Prelude Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Prelude Therapeutics has a total shareholder equity of $237.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $277.7M and $40.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$232.94m |
| Equity | US$237.09m |
| Total liabilities | US$40.58m |
| Total assets | US$277.67m |
Recent financial health updates
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Sep 17
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Jan 28We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
Oct 27We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Jun 28Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Mar 14Recent updates
Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Feb 03Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Sep 17We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Jan 28We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
Oct 27Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Oct 18Prelude downgraded at Morgan Stanley ahead of key update
Sep 09We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Jun 28Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Mar 14We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
Dec 14Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Jul 05What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?
Feb 16
Prelude Therapeutics prices $150M share offering
Jan 07Prelude Therapeutics readies public offering
Jan 04Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares
Dec 25Financial Position Analysis
Short Term Liabilities: PRLD's short term assets ($235.6M) exceed its short term liabilities ($21.8M).
Long Term Liabilities: PRLD's short term assets ($235.6M) exceed its long term liabilities ($18.7M).
Debt to Equity History and Analysis
Debt Level: PRLD is debt free.
Reducing Debt: PRLD had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRLD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PRLD has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 31% each year.